Form 4: Baxter International EVP Christopher A. Toth Reports Acquisition of Restricted Stock Units

Christopher A. Toth, EVP of Baxter International, reports the acquisition of restricted stock units (RSUs) as part of his annual equity grant.

Summary

• Christopher A. Toth, an Executive Vice President at Baxter International Inc., filed a Form 4 on March 8, 2024, reporting a transaction that occurred on March 6, 2024.
• The transaction involved the acquisition of 119,076 shares of Baxter's common stock in the form of restricted stock units (RSUs) granted as part of his 2024 annual equity grant.
• These RSUs will vest in three equal annual installments starting on March 6, 2025, subject to meeting the vesting requirements outlined in Baxter's 2021 Incentive Plan.
• Following the reported transaction, Toth beneficially owns 227,761 shares of Baxter common stock, which includes the automatic reinvestment of dividends.
• Toth has a power of attorney naming David S. Rosenbloom, Ellen K. Bradford, and Kimberly Olson as his attorneys-in-fact for Section 16 filings.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the executive's continued contributions. There are no explicit negative indicators.

Positives

• The acquisition of RSUs indicates continued alignment of the executive's interests with the company's long-term performance.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the equity grant suggests an expectation of continued contributions from the executive.

Industry Context

Equity grants are a common practice in the pharmaceutical and medical device industry to incentivize and retain key executives. The vesting schedule aligns the executive's interests with the long-term performance of the company, which is a standard practice.

Comparison to Industry Standards

• Equity compensation is a standard practice among publicly traded companies, including Baxter's competitors such as Medtronic, Johnson & Johnson, and Abbott Laboratories.
• The size and vesting schedule of the RSU grant are likely determined based on industry benchmarks for executive compensation, considering the executive's role and responsibilities within the company.
• Similar companies often use a mix of stock options, restricted stock units, and performance-based equity awards to align executive compensation with shareholder value creation.

Stakeholder Impact

• The equity grant aligns the executive's interests with those of shareholders, potentially encouraging decisions that benefit long-term shareholder value.
• The grant serves as an incentive for the executive, potentially boosting morale and productivity.

Key Dates